Compare · MCRB vs ONTX
MCRB vs ONTX
Side-by-side comparison of Seres Therapeutics Inc. (MCRB) and Onconova Therapeutics Inc. (ONTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MCRB and ONTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MCRB is the larger of the two at $50.2M, about 1.4x ONTX ($36.3M).
- Over the past year, MCRB is down 75.4% and ONTX is down 53.2% - ONTX leads by 22.2 points.
- MCRB has hit the wire 11 times in the past 4 weeks while ONTX has been quiet.
- MCRB has more recent analyst coverage (10 ratings vs 1 for ONTX).
- Company
- Seres Therapeutics Inc.
- Onconova Therapeutics Inc.
- Price
- $4.80-4.48%
- $17.00-7.96%
- Market cap
- $50.2M
- $36.3M
- 1M return
- -0.62%
- -5.76%
- 1Y return
- -75.36%
- -53.17%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2013
- News (4w)
- 11
- 0
- Recent ratings
- 10
- 1
Seres Therapeutics Inc.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Onconova Therapeutics Inc.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Latest MCRB
- SEC Form EFFECT filed by Seres Therapeutics Inc.
- Officer Brady Kelly sold $291 worth of shares (64 units at $4.55) as part of a pre-agreed trading plan and converted options into 181 shares, increasing direct ownership by 1% to 8,679 units (SEC Form 4)
- Director Shaff Eric D. converted options into 722 shares and sold $1,197 worth of shares (263 units at $4.55) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 12,499 units (SEC Form 4)
- Officer Henn Matthew R converted options into 238 shares and sold $369 worth of shares (81 units at $4.55) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 7,995 units (SEC Form 4)
- Officer Desrosier Thomas sold $373 worth of shares (82 units at $4.55) as part of a pre-agreed trading plan and converted options into 245 shares, increasing direct ownership by 2% to 8,117 units (SEC Form 4)
- SEC Form S-3 filed by Seres Therapeutics Inc.
- SEC Form 10-Q filed by Seres Therapeutics Inc.
- Seres Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
- Seres Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
Latest ONTX
- SEC Form 10-K/A filed by Onconova Therapeutics Inc. (Amendment)
- SEC Form D filed by Onconova Therapeutics Inc.
- SEC Form DEFA14A filed by Onconova Therapeutics Inc.
- Onconova Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- New insider Orbimed Advisors Llc claimed ownership of 1,045,261 shares (SEC Form 3) (Amendment)
- New insider Tpav, Llc claimed ownership of 1,222,738 shares (SEC Form 3) (Amendment)
- SEC Form SC 13D filed by Onconova Therapeutics Inc.
- Redfield Robert was granted 97,500 shares (SEC Form 4)
- Pauza Charles David was granted 97,500 shares (SEC Form 4)
- Cautreels Werner was granted 200,000 shares (SEC Form 4)